| [1] |
中华医学会感染病学分会，GRADE中国中心．中国乙型肝炎病毒母婴传播防治指南(2019年版)[J]．中华传染病杂志，2019，37(7):388-396.
|
| [2] |
赵英仁．提升指南制订标准，更好指导中国乙型肝炎病毒母婴传播阻断的临床实践[J]．中华传染病杂志，2019, 37(7):385-387.
|
| [3] |
中华医学会感染病学分会，GRADE中国中心．中国乙型肝炎病毒母婴传播防治指南(2019年版)[J]．中华临床感染病杂志，2019，12(5):321-330.
|
| [4] |
周乙华，李彤，庄辉．对"《中国乙型肝炎病毒母婴传播防治指南(2019年版)》"的商榷[J]．临床肝胆病杂志，2020, 36(1):59-61.
|
| [5] |
Fu S, Yao N, Feng Y, et al. Dynamic changes of HBsAg and/or HBV DNA in infants born to HBsAg(＋) mothers: A systematic review and meta-analysis[J]. Hepatology, 2019, 70 Suppl 1:581A-581A.
|
| [6] |
Zhang L, Gui XE, Wang B, et al. Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates[J]．BMC Infect Dis, 2016，16(1):408-417.
|
| [7] |
Chen T, Wang J, Feng Y, et al. Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg (＋) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants？[J]. BMC Infect Dis, 2013, 13:524-531.
|
| [8] |
Lu Y, Liang XF, Wang FZ, et al. Hepatitis Bvaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg (＋)/ HBeAg (-) mothers[J]. Vaccine, 2017，35(1):40-45.
|
| [9] |
Zou H, Chen Y, Duan Z, et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg positive mothers[J]．J Viral Hepat, 2012，19(2):e18-25.
|
| [10] |
Yuan J, Lin J, Xu A, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study[J]．J Viral Hepat, 2006，13(9):597-604.
|
| [11] |
Chen HL, Zha ML, Cai JY, et al. Maternal viral load and hepatitis B virus mother-to-child transmission risk: a systematic review and meta-analysis[J]. Hepatol Res, 2018，48(10):788-801.
|
| [12] |
Cheung KW, Seto MTY, Kan ASY, et al. Immunoprophylaxis failure of infants born to hepatitis B carrier mothers following routine vaccination[J]. Clin Gastroenterol Hepatol, 2018，16(1):144-145.
|
| [13] |
Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016，374(24):2324-2334.
|
| [14] |
Tsai PJ, Chang A, Yamada S, et al. Use of Tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women[J]. Dig Dis Sci, 2014，59(11):2797-2803.
|
| [15] |
Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J]. Hepatology, 2014，60(2):468-476.
URL
|
| [16] |
中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南2019年版[J]. 临床肝胆病杂志，2019，35(12):2648-2669.
|
| [17] |
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]．J Hepatol, 2017，67(2):370-398.
|
| [18] |
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018，67(4):1560-1599.
|
| [19] |
Castillo E, Murphy K, van Schalkwyk J．No. 342-Hepatitis B and pregnancy[J]. J Obstet Gynaecol Can, 2017，39(3):181-190.
|
| [20] |
Yang Y, Jin L, He YL, et al. Hepatitis B virus infection inclustering of infection in families with unfavorable prognoses innorthwest China[J]．J Med Virol, 2013，85(11):1893-1899.
|
| [21] |
Chen T, Wang J, Qiu H, et al. Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(＋) or HBeAg(-)[J]. Med (Baltimore), 2018，97(27):e11406.
|
| [22] |
Lu Y, Zhu FC, Liu JX，et al. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China[J]. Vaccine, 2017，35(48 Pt B):6627-6633.
|
| [23] |
Sun KX, Li J, Zhu FC, et al. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women[J]. Vaccine，2012，30(36):5335-5340.
URL
|
| [24] |
Yang X, Zhong X, Liao H, et al. Efficacy of antiviral therapy during the second or the third trimester for preventing mother-to-child hepatitis B virus transmission: a systematic review and meta-analysis[J]. Rev Inst Med Trop Sao Paulo, 2020，62:e13
|
| [25] |
Wu Y, Liu J, Feng Y, et al. Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis[J]. Hepatol Int, 2020，14(2):180-189.
|
| [26] |
Song J, Yang F, Wang S, et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis[J]. J Viral Hepat, 2019，26(3):397-406.
|
| [27] |
Li J, Chang MS, Tran TT, et al. Management of Chronic Hepatitis B in Pregnancy[J]. J Clin Gastroenterol, 2017，51(9):789-795.
|
| [28] |
Thilakanathan C, Wark G, Maley M, et al. Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing[J]. Liver Int, 2018，38(7):1212-1219.
|
| [29] |
Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis[J]. Hepatol, 2016, 63:319-333.
|
| [30] |
Chen J Z, Liao Z W, Huang F L, et al. Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load[J]．Sci Rep, 2017，7(1):4132.
|
| [31] |
Sali S, Darvishi M, GhasemiAdl M, et al. Comparing the efficacy and safety of treating chronic hepatitis B infection during pregnancy with Lamivudine, Telbivudine, and Tenofovir: a meta-analysis[J]. J Clin Transl Hepatol, 2019，7(3):197-212
|
| [32] |
Tavakolpour S, Darvishi M, Mirsafaei HS, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review[J]. Infect Dis (Lond), 2018，50(2):95-106.
|
| [33] |
Hyun MH, Lee YS, Kim JH, et al. Systematic review with meta-analysis: The efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis Bvirus[J]．Aliment Pharmacol Ther, 2017, 45(12):1493-1505.
|
| [34] |
Zhou C, Yu Y, Yang Q, et al. Motor development delay in offspring is associated with prenatal telbivudine exposure[J]．Medicine (Baltimore). 2018，97(9): e0053
|
| [35] |
Wen WH, Chen HL, Shih TT, et al. Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate[J]．J Hepatol，2020，72(6): 1082-1087.
|
| [36] |
Chang CY, Aziz N, Poongkunran M, et al. Serum alanine aminotransferase and Hepatitis B DNA flares in pregnant and postpartum women with chronichepatitisB[J]. Am J Gastroenterol, 2016，111 (10):1410-1415.
|
| [37] |
Chang CY, Aziz N, Poongkunran M, et al. Serum aminotransferase flares in pregnant and postpartum women with current or prior treatment for chronic hepatitis B[J]．J Clin Gastroenterol，2018，52 (3):255-261.
|
| [38] |
Nguyen V, Tan PK, Greenup AJ, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare[J]. Aliment Pharmacol Ther, 2014，39(10):1225-1234.
|
| [39] |
Nguyen V, Tan PK, Greenup AJ, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare[J]. Aliment Pharmacol Ther，2014，39(10):1225-1234.
|
| [40] |
Yi W, Pan CQ, Hao J, et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers[J]．J Hepatol，2014，60(3):523-529.
URL
|
| [41] |
Han Z, Zhang Y, Bai X, et al. Mother-to-child transmission of hepatitis B virus after amniocentesis: a retrospective matched-cohort study[J]. Prenat Diagn, 2019，39(6):431-440.
|
| [42] |
Mak JSM, Leung MBW, Chung CHS, et al. Presence of Hepatitis B virus DNA in follicular fluid in female Hepatitis B carriers and outcome of IVF/ICSI treatment: A prospective observational study[J]. Eur J Obstet Gynecol Reprod Biol, 2019，239:11-15.
|
| [43] |
Wang L, Li L, Huang C, et al. Maternal chronic hepatitis B virus infection does not affect pregnancy outcomes in infertile patients receiving first in vitro fertilization treatment[J]. FertilSteril, 2019, 112(2):250-257.e1.
|
| [44] |
Peng S, Wan Z, Liu T, et al. Cesarean section reduces the risk of early mother-to-child transmission of hepatitis B virus[J]. Dig Liver Dis, 2018，50(10):1076-1080.
|
| [45] |
Pan CQ, Zou HB, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J]．Clin Gastroenterol Hepatol, 2013，11(10):1349-1355.
|
| [46] |
Yang M, Qin Q, Fang Q, et al. Cesarean section to prevent mother-tochild transmission of hepatitis B virus in China: A meta-analysis[J]. BMC Pregnancy Childbirth, 2017，17(1):303.
|
| [47] |
Chen HL, Cai JY, Song YP, et al. Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: A systematic review and a meta-analysis[J]. Midwifery, 2019, 74:116-125.
|
| [48] |
Yin Y, Wu L, Zhang J, et al. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus[J]. J Infect, 2013, 66:447-452.
|
| [49] |
Chen X, Chen J, Wen J, et al. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus[J]. PLoS One, 2013，8(1): e55303
|
| [50] |
Zhang L, Gui X, Fan J, et al. Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus[J]. J Matern Fetal Neonatal Med, 2014, 27: 182-186.
|
| [51] |
Jacobson DL, Patel K, Williams PL, et al. Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal[J]. Pediatr Infect Dis J, 2017，36(2):189-197.
|
| [52] |
Zou H, Chen Y, Duan Z, et al.Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers[J]．PLoS One, 2011，6(10):e26748。
|
| [53] |
Bzowej NH, Tran TT, Li R, et al. Total alanine aminotransferase (ALT) flares in pregnant north American women with chronic hepatitis B infection: results from a prospective observational study[J]. Am J Gastroenterol，2019，114(8):1283-1291.
|